The results of Grifols’ AMBAR (Alzheimer Management by Albumin Replacement) clinical trial, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, show that plasma exchange with albumin replacement can slow Alzheimer’s disease progression. The therapy, which removes amyloid-beta protein bound to albumin from the blood, demonstrated benefits in cognitive and functional decline for Alzheimer’s patients.

This study supports plasma exchange as a potential treatment for Alzheimer’s, offering a new approach that could complement existing therapies. Grifols is working on further advancing this treatment approach.